Immunocore Holdings plc (NASDAQ:IMCR) Receives $65.64 Consensus Price Target from Analysts

Immunocore Holdings plc (NASDAQ:IMCR) has earned an average rating of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $65.64.

IMCR has been the subject of several research analyst reports. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Thursday, October 24th. Needham & Company LLC restated a “buy” rating and set a $71.00 price target on shares of Immunocore in a research note on Friday. Guggenheim lowered Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th.

Immunocore Stock Up 0.6 %

IMCR stock opened at $30.40 on Friday. The firm has a market cap of $1.52 billion, a PE ratio of -32.00 and a beta of 0.76. Immunocore has a one year low of $27.69 and a one year high of $76.98. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The firm’s 50 day moving average price is $31.16 and its 200-day moving average price is $33.75.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. The business had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.59) EPS. On average, equities research analysts anticipate that Immunocore will post -0.94 EPS for the current year.

Institutional Trading of Immunocore

A number of large investors have recently made changes to their positions in the company. Primecap Management Co. CA grew its holdings in Immunocore by 26.7% during the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after acquiring an additional 520,950 shares in the last quarter. State Street Corp grew its stake in shares of Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after purchasing an additional 29,897 shares in the last quarter. Candriam S.C.A. increased its holdings in Immunocore by 65.8% in the second quarter. Candriam S.C.A. now owns 313,423 shares of the company’s stock valued at $10,621,000 after buying an additional 124,417 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Immunocore in the second quarter valued at $3,686,000. Finally, Principal Financial Group Inc. lifted its holdings in Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after buying an additional 109,206 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.